The most common forms of hereditary motor and sensory neuropathies (HMSN) or Charcot-MarieTooth disease (CMT) are associated with mutations affecting myelin genes in the peripheral nervous system. A minor subgroup of CMT type 1A (CMT1A) is caused by point mutations in the gene encoding the peripheral myelin protein 22 (PMP22). To study the mechanisms by which these mutations cause the CMT pathology, we transiently transfected COS7 and Schwann cells with wild-type and PMP22 expression constructs carrying six representative dominant or de novo point mutations and one putative recessive point mutation. All but one of the first group of mutant PMP22 proteins failed to be incorporated into the plasma membrane and were retained in intracellular compartments of transfected cells. Surprisingly, the recessive PMP22 mutation produced a protein that was also mildly impaired in trafficking. Thus, our results suggest a common disease mechanism underlying the pathology of CMT1A due to PMP22 point mutations.
INTRODUCTION
Hereditary motor and sensory neuropathies (HMSN) are a large and heterogeneous group of disorders that are classified in several subgroups based on clinical, electrophysiological, and morphological criteria (for review, see Dyck et al., 1993; Gabreels-Festen et al., 1993) . The most common form is Charcot-MarieTooth disease type 1 (CMT1), which is characterized by a dominant trait of inheritance and an estimated prevalence of approximately 1:10,000 (Nelis et al., 1996) . The onset of clinical symptoms of CMT1 patients is mainly in the second to third decade of life and is characterized by progressive weakness of the distal muscles with mild sensory impairment and markedly reduced nerve conduction velocities (NCV). Morphologically, nerves of CMT1 patients show demyelination, remyelination, onion bulb formation, and loss of myelinated axons (Lupski et al., 1991a) . Recent advances in molecular biology have revealed several genetic defects leading to the CMT1 phenotype (reviewed in Snipes & Suter, 1995) . The most frequent form, termed CMT1A, is associated with a 1.5-megabase tandem duplication in the chromosomal region 17p11.2-p12, including the gene for peripheral myelin protein 22 (PMP22; Lupski et al., 1991b; Matsunami et al., 1992; Patel et al., 1992; Raeymaekers et al., 1991; Timmerman et al., 1992; Valentijn et al., 1992a) . Based on these findings, it was proposed that a gene-dosage effect of PMP22 might be causative for the disease. This hypothesis has been confirmed by the generation of transgenic rodents carrying additional copies of the PMP22 gene and the quantitative analysis of biopsies of CMT1A patients (Huxley et al., 1996 (Huxley et al., , 1998 Magyar et al., 1996; Sereda et al., 1996; Vallat et al., 1996) . Deletions of the same chromosomal segment that is duplicated in CMT1A are linked to the mild hereditary neuropathy with liability to pressure palsies (HNPP; Chance et al., 1993; Lopes et al., 1997) . Formal proof for the crucial role of PMP22 dosage in this neuropathy has been gained from the analysis of genetically engineered PMP22-deficient mice (Adlkofer et al., 1995 (Adlkofer et al., , 1997a . Furthermore, several distinct
